DE2315801C3 - 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate - Google Patents

2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate

Info

Publication number
DE2315801C3
DE2315801C3 DE2315801A DE2315801A DE2315801C3 DE 2315801 C3 DE2315801 C3 DE 2315801C3 DE 2315801 A DE2315801 A DE 2315801A DE 2315801 A DE2315801 A DE 2315801A DE 2315801 C3 DE2315801 C3 DE 2315801C3
Authority
DE
Germany
Prior art keywords
pyrazolo
pyridine
alkyl
pyridines
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2315801A
Other languages
German (de)
English (en)
Other versions
DE2315801A1 (de
DE2315801B2 (de
Inventor
Junji Kitamoto Hatayama
Masayuki Ageo Hayashi
Etsuko Urawa Hetsugi
Tsutomu Tokio Irikura
Kikuo Koshirae
Yoshitaka Kudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of DE2315801A1 publication Critical patent/DE2315801A1/de
Publication of DE2315801B2 publication Critical patent/DE2315801B2/de
Application granted granted Critical
Publication of DE2315801C3 publication Critical patent/DE2315801C3/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE2315801A 1972-03-30 1973-03-29 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate Expired DE2315801C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (enExample) 1972-03-30 1972-03-30

Publications (3)

Publication Number Publication Date
DE2315801A1 DE2315801A1 (de) 1973-10-11
DE2315801B2 DE2315801B2 (de) 1978-06-22
DE2315801C3 true DE2315801C3 (de) 1979-02-22

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2315801A Expired DE2315801C3 (de) 1972-03-30 1973-03-29 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate

Country Status (12)

Country Link
US (1) US3850941A (enExample)
JP (1) JPS5229318B2 (enExample)
AR (1) AR197709A1 (enExample)
BE (1) BE797554A (enExample)
BR (1) BR7302268D0 (enExample)
CA (1) CA989843A (enExample)
DE (1) DE2315801C3 (enExample)
ES (1) ES413188A1 (enExample)
FR (1) FR2182914B1 (enExample)
GB (1) GB1378375A (enExample)
HU (1) HU167305B (enExample)
SE (1) SE402592B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (enExample) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
ES2362998T3 (es) 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
CN1812983A (zh) 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
AU2004292445B2 (en) 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CA2654498A1 (en) * 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
PL2131841T3 (pl) 2007-01-30 2013-03-29 Avigen Inc Sposoby leczenia bólu ostrego
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
AU2008273050A1 (en) * 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
TW200922569A (en) * 2007-08-10 2009-06-01 Genelabs Tech Inc Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009022740A1 (ja) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010005520A2 (en) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
HK1218629A1 (zh) 2013-02-25 2017-03-03 Bausch Health Ireland Limited 用於结肠清洁的鸟苷酸环化酶受体激动剂
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
CA3125765A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Also Published As

Publication number Publication date
DE2315801A1 (de) 1973-10-11
GB1378375A (en) 1974-12-27
SE402592B (sv) 1978-07-10
AR197709A1 (es) 1974-04-30
CA989843A (en) 1976-05-25
FR2182914B1 (enExample) 1976-05-14
BE797554A (fr) 1973-07-16
AU5376173A (en) 1974-09-26
JPS5229318B2 (enExample) 1977-08-01
FR2182914A1 (enExample) 1973-12-14
HU167305B (enExample) 1975-09-27
DE2315801B2 (de) 1978-06-22
JPS4897898A (enExample) 1973-12-13
BR7302268D0 (pt) 1974-08-29
US3850941A (en) 1974-11-26
ES413188A1 (es) 1976-01-16

Similar Documents

Publication Publication Date Title
DE2315801C3 (de) 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate
DE2734678C2 (de) Epininester,Verfahren zu ihrer Herstellung und Heilmittel
DE2359536C2 (de) 2,6-Diaminonebularinderivate
EP0049407A1 (de) 6-Hydroxy-2-phenyl-imidazo(4,5-b)pyridine, ihre Herstellung und diese enthaltende Arzneimittel
DE69413398T2 (de) Positiv inotropische und lusitropische pyrrolochinolinonderivate
DE3940021C2 (de) Adenosin-Derivate, deren Herstellung und Verwendung
DE3889644T2 (de) Pheophorbidderivate.
DE2155578B2 (de) Verfahren zur Herstellung von 8,9-Didehydro-10-alkoxy-ergolenderivaten
EP0184738A2 (de) Neue Imidazoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE2539867C2 (de) 14,15-Dihydro-3β ,16α -eburnameninderivate
CH649999A5 (de) 10-brom-e-homo-eburnane.
DE2634910C3 (de) Quartare l>Benzylimidazo [1,2-a] pyridiniumsalze und diese enthaltende pharmazeutische Zubereitung
DE2520131C3 (de) 1,1,-Disubstituierte Octahydro-indolo[2,3-a]chinolizine und verfahren zu deren Herstellung
DE2221808C2 (de) Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
DE69221006T2 (de) Mitomycinderivate
DE3876859T2 (de) Cardiotonische tricyclische oxazolone.
DE1242619B (de) Verfahren zur Herstellung von neuen Nikotionsaeureestern
DE2155469C2 (de) 5-Hydroxy-5-(1-phenyläthyl)-barbitursäure-Derivate, Verfahren zu deren Herstellung und diese enthaltende analgetische Mittel
DE2444890A1 (de) Quaternaere 7-substituierte imidazoeckige klammer auf 2,1-b eckige klammer zu -thiazolderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE60004054T2 (de) Neue verfahren zur herstellung von 17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstane-3-on
DE2559558C3 (de) Apovincaminsäureamide, deren Salze mit Säuren, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2328758C2 (de) 4,4-Diphenyl-2-methyl-2-hydroxybutylamine und diese enthaltende therapeutische Zubereitungen
DD236095A5 (de) Verfahren zur herstellung von neuen nitronpovincamsaeure-derivaten
DE2404924A1 (de) Ergolinderivate
DE2732906C2 (de) In 5-Stellung durch einen Aminoalkylrest substituierte Imidazo-isochinolin-dione, Verfahren zu ihrer Herstellung und Arzneimittel

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)